March 2, 2018 – XYMOGEN, Inc., a leading manufacturer of medical foods and dietary supplements, announced today that is has prevailed in a lawsuit with Thorne Research. On February 20, 2018, after a six-day trial, a jury in the United States District Court for the District of Utah ruled for XYMOGEN. The jury found that XYMOGEN’s proprietary and highly-absorbed CoQMax product was actually invented by a chemist from XYMOGEN’s manufacturer thereby invalidating Thorne’s patent on their product.
“I am extremely pleased that the jury saw fit to discredit Thorne’s claims and invalidate their patent”, said Brian Blackburn, XYMOGEN’s Founder and CEO. “Claiming a patent on an invention by a third-party misleads the public, and I hope the jury’s verdict will deter others from similar practices.”
About XYMOGEN:
To learn more about XYMOGEN, a family-owned, health sciences company, and its formulas, distribution, and community involvement, visit XYMOGEN.com, email pr@xymogen.com, or call 800-647-6100. XYMOPrint, a full-service digital printer and design studio, XYMOGEN LOGISTICS, a third-party fulfillment, warehousing, and shipping provider; and PharmaceutiX Medical Foods are all subsidiaries of XYMOGEN.
6900 Kingesporte Parkway
Orlando, Fl
Tel: 800-647-6100
info@xymogen.com
Attachment:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3a48371c-6283-4c53-afa1-bb7a889b35d1